查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541129

2024-2032 年按疫苗類型、產品類型、配銷通路（分銷合作夥伴公司、非政府組織、政府機構）、最終用戶和地區分類的肺炎球菌疫苗市場報告

Pneumococcal Vaccine Market Report by Vaccine Type, Product Type, Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, Government Authorities), End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2023年全球肺炎鏈球菌疫苗IMARC Group規模達94億美元。市場的促進因素包括敗血症和肺炎疾病的增加、人口老化、醫療保健支出的增加、管理機構的舉措和資金、監管支持和批准、公共衛生運動以及疫苗技術的進步。

肺炎鏈球菌疫苗市場分析：

主要市場促進因素：目標疾病數量的增加以及全球管理機構的措施正在促進市場成長。

主要市場趨勢：研發（R＆D）活動投資的增加和肺炎疾病數量的增加正在對市場產生積極影響。

地理趨勢：由於強大的醫療基礎設施和持續的技術創新，北美佔據了最大的市場佔有率。

競爭格局：肺炎鏈球菌疫苗產業的一些主要市場參與者包括 Astellas Pharma Inc.、GlaxoSmithKline Plc.、Merck & Co. Inc.、Panacea Biotec Ltd.、Pfizer Inc.、Sanofi SA、Serum Institute of India Pvt Ltd 和沃森生物科技有限公司等。

挑戰與機會：雖然市場面臨與疫苗相關的醫療問題等影響市場的挑戰，但在新型疫苗的開發和批准方面也遇到了機會。

肺炎鏈球菌疫苗市場成長因素：

醫療保健支出不斷增加

高醫療保健支出使政府和私人醫療保健部門能夠在疫苗接種計劃上投入更多資金，從而提高肺炎球菌疫苗的可及性和成本效益，從而提高人群的疫苗接種覆蓋率。與此一致，增加醫療保健支出通常會轉化為更好的醫療保健基礎設施，包括疫苗接種診所、分銷網路和訓練有素的醫療保健專業人員。該基礎設施有助於肺炎球菌疫苗的管理和宣傳，從而促進市場的成長。此外，高醫療保健支出可能會導致製藥公司增加對研發（R&D）活動的​​投資，從而鼓勵改進效果更好、覆蓋更多血清型或需要更少劑量的肺炎球菌疫苗。根據美國醫療保險和醫療補助服務中心網站2024年更新的內容，預計醫療支出將佔GDP的比重將從2022年的17.3%增加到2032年的19.7%。

人口老化加劇

由於免疫系統減弱和潛在的健康狀況，老年人更容易患肺炎球菌感染，包括肺炎或侵襲性肺炎球菌疾病。這種日益增加的脆弱性導致人們高度利用肺炎球菌疫苗來避免此類嚴重疾病。除此之外，許多管理機構和醫療機構建議將老年人肺炎球菌疫苗接種作為常規免疫計劃的一部分，這鼓勵醫療保健提供者和老年人優先接種疫苗，從而推動肺炎球菌疫苗的需求。此外，醫療保健部門優先考慮針對老齡化人口的預防性護理策略，以改善他們的健康並最大限度地減少再入院率。世界衛生組織（WHO）網站上發表的一篇文章顯示，到2050年，全球60歲以上的人口預計將增加一倍，達到近21億。

敗血症盛行率增加

根據世界衛生組織（WHO）網站2024年更新的內容，全球估計膿毒症病例中近2000萬例發生在5歲以下兒童身上。引起肺炎球菌感染的肺炎鏈球菌是敗血症的主要原因之一，特別是在免疫系統較弱的兒童。肺炎鏈球菌感染引起的敗血症發生率不斷上升，凸顯了疫苗接種等預防措施的重要性。此外，接種肺炎鏈球菌疫苗可顯著降低肺炎球菌感染的風險，包括那些可能導致敗血症的風險。透過預防肺炎球菌疾病，疫苗有助於減輕醫療機構敗血症的整體負擔。除此之外，它們還透過預防肺炎球菌疾病來減輕護理機構敗血症的整體負擔。此外，肺炎球菌疫苗作為預防敗血症的保護策略正在增加其銷售量。透過全球公共衛生干預中的疫苗接種來預防敗血症發病率和死亡率正在支持市場成長。

肺炎鏈球菌疫苗市場細分：

IMARC Group提供了每個細分市場的肺炎球菌疫苗產業趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據疫苗類型、產品類型、配銷通路和最終用戶對市場進行了分類。

依疫苗類型細分：

肺炎鏈球菌結合疫苗

肺炎鏈球菌多醣體疫苗

肺炎鏈球菌結合疫苗佔據大部分市場佔有率

該報告根據疫苗類型對市場進行了詳細的細分和分析。這包括肺炎鏈球菌結合疫苗和肺炎鏈球菌多醣體疫苗。根據該報告，肺炎鏈球菌結合疫苗佔據了最大的佔有率。

肺炎鏈球菌結合疫苗 (PCV) 是市場上最重要的產品之一，因為它可以有效改善公眾健康，特別是五歲以下兒童和老年人的健康。 PCV 旨在提供各種血清型肺炎鏈球菌的保護，已知這種細菌會導致嚴重甚至有時致命的疾病，例如肺炎、腦膜炎和敗血症。 PCV已被證明可以有效降低這些疾病的發生率，這使得將其納入國家免疫規劃成為可能。

按產品類型分類：

普雷夫納爾 13

合成花

肺炎疫苗23

Prevnar 13 佔據業界第一佔有率

報告還根據產品類型對市場進行了詳細的細分和分析。其中包括 Prevnar 13、synflorix 和 pneumovax 23。

Prevnar 13 因其可有效預防肺炎鏈球菌引起的感染而備受青睞。這種疫苗因其廣泛覆蓋 13 種不同的細菌菌株而特別引人注目。將其納入世界各地的國家免疫計劃極大地影響了肺炎球菌疾病的病例，尤其是幼兒和老年人。此外，其良好的臨床有效性和安全性確保了其在世界各地的廣泛使用，使其成為現代醫療保健系統對抗肺炎球菌疾病的重要支柱。

按配銷通路分類：

分銷合作夥伴公司

非政府組織 (NGO)

政府機關

非政府組織 (NGO) 代表了主要的細分市場

該報告根據配銷通路對市場進行了詳細的細分和分析。這包括分銷合作夥伴公司、非政府組織 (NGO) 和政府當局。根據該報告，非政府組織（NGO）佔最大部分。

非政府組織(NGO) 透過各種措施為市場動態做出貢獻，包括為疫苗接種計劃提供資金支持、提高對肺炎球菌免疫重要性的認知，以及與政府和製藥公司合作確保疫苗的可負擔性和可用性。非政府組織也參與研發活動，以提高疫苗效力並促進針對兒童和老年人等弱勢群體的疫苗接種活動。他們的宣傳工作也解決了醫療保健取得方面的社會經濟差異，使肺炎球菌疫苗在全球範圍內更容易獲得和產生影響。

按最終用戶分類：

兒科

成年人

報告還提供了基於最終用戶的詳細市場細分和分析。這包括兒科和成人。

兒童，尤其是嬰兒和幼兒，非常容易受到肺炎球菌感染，這可能導致嚴重的疾病，例如肺炎、腦膜炎和敗血症。因此，建議將肺炎鏈球菌疫苗接種作為全球兒童常規免疫計劃的一部分。肺炎鏈球菌疫苗在預防這些感染方面的有效性正在顯著降低全球兒童的發病率和死亡率。此外，針對兒科族群的公共衛生措施和免疫計畫正在為肺炎球菌疫苗市場統計做出貢獻。

隨著成年人的衰老，尤其是 65 歲以上或有潛在健康問題的成年人，他們變得更容易受到肺炎球菌感染，這可能導致嚴重的疾病，如肺炎、腦膜炎和敗血症。成人疫苗接種有助於降低這些感染及其相關併發症的風險，改善整體健康並降低醫療費用。此外，成年人通常是肺炎球菌的攜帶者，有可能將其傳播給兒童和老年人等更脆弱的人。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的肺炎球菌疫苗市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是肺炎鏈球菌疫苗最大的區域市場。

根據醫療保險和醫療補助服務中心網站 2023 年更新的內容，2022 年美國醫療保健支出成長 4.1%，達到 4.5 兆美元，即人均 13,493 美元。醫療保健支出的增加反映出人們更加重視透過創新技術改善患者的治療結果並降低整體醫療保健成本。此外，北美擁有嚴格的監管框架和政府對免疫計劃的大力支持，這對市場的成長做出了重大貢獻。北美肺炎球菌疾病的流行，加上醫療保健專業人員和一般民眾對疫苗接種益處的認知不斷提高，也推動了對肺炎球菌疫苗的需求。

競爭格局：

市場肺炎球菌疫苗市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。肺炎鏈球菌疫苗產業的一些主要市場參與者包括 Astellas Pharma Inc.、GlaxoSmithKline Plc.、Merck & Co. Inc.、Panacea Biotec Ltd.、Pfizer Inc.、Sanofi SA、Serum Institute of India Pvt Ltd 和 Walvax Biotechnology有限公司

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

主要參與者正在投資旨在開發下一代疫苗配方的研發（R&D）活動。他們也正在擴大製造能力，以滿足不斷成長的全球需求。主要參與者也投資於臨床試驗和研究，以證明有效性和安全性。他們也採用創新技術進行疫苗生產和分配。許多公司正在實施疫苗接種活動和教育計劃，以提高意識和疫苗接種率。主要參與者正在與其他行業利益相關者、政府機構、醫療保健組織和研究機構合作，擴大市場範圍並開發新產品。例如，2023 年，Vaxcyte, Inc. 與 Lonza 合作達成了一項新的商業製造協議。透過此次合作，Vaxcyte 計劃擴大其 PCV 候選藥物的商業生產能力。

肺炎鏈球菌疫苗市場最新消息：

2024 年 1 月 26 日：輝瑞的 20 價肺炎鏈球菌結合疫苗候選藥物 (20vPnC) 獲得歐洲藥品管理局 (EMA) 人用藥品委員會 (CHMP) 的行銷授權。

2024 年 4 月 22 日：武田、安斯泰來和三井住友銀行宣布達成協議，成立合資公司，孵化早期藥物發現計畫。

本報告回答的關鍵問題

  • 2023年全球肺炎鏈球菌疫苗市場規模是多少
  • 2024-2032年全球肺炎鏈球菌疫苗市場的預期成長率是多少
  • COVID-19 對全球肺炎鏈球菌疫苗市場有何影響
  • 推動全球肺炎鏈球菌疫苗市場的關鍵因素是什麼
  • 根據疫苗類型，全球肺炎鏈球菌疫苗市場的細分如何
  • 根據產品類型，全球肺炎鏈球菌疫苗市場的細分如何
  • 從配銷通路來看，全球肺炎鏈球菌疫苗市場的細分如何
  • 全球肺炎鏈球菌疫苗市場的重點區域有哪些
  • 誰是全球肺炎鏈球菌疫苗市場的主要參與者/公司

本報告回答的關鍵問題

  • 2023年全球肺炎鏈球菌疫苗市場規模有多大？ 2024-2032年全球肺炎鏈球菌疫苗市場的預期成長率是多少？
  • COVID-19 對全球肺炎鏈球菌疫苗市場有何影響？
  • 推動全球肺炎鏈球菌疫苗市場的關鍵因素是什麼？
  • 根據疫苗類型，全球肺炎鏈球菌疫苗市場的分佈如何？
  • 根據產品類型，全球肺炎鏈球菌疫苗市場的細分如何？
  • 根據配銷通路，全球肺炎鏈球菌疫苗市場的細分如何？
  • 全球肺炎鏈球菌疫苗市場的重點區域有哪些？
  • 全球肺炎鏈球菌疫苗市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球肺炎鏈球菌疫苗市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依疫苗類型

  • 肺炎鏈球菌結合疫苗
    • 市場趨勢
    • 市場預測
  • 肺炎鏈球菌多醣體疫苗
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依產品類型

  • 普雷夫納爾 13
    • 市場趨勢
    • 市場預測
  • 合成花
    • 市場趨勢
    • 市場預測
  • 肺炎疫苗23
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 分銷合作夥伴公司
    • 市場趨勢
    • 市場預測
  • 非政府組織 (NGO)
    • 市場趨勢
    • 市場預測
  • 政府機關
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 兒科
    • 市場趨勢
    • 市場預測
  • 成年人
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc.
    • Merck & Co. Inc.
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Pvt Ltd.
    • Walvax Biotechnology Co. Ltd.
Product Code: SR112024A3133

The global pneumococcal vaccine market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032. The market is driven by the growing occurrence of sepsis and pneumonia diseases, rising aging population, increasing healthcare spending, governing agencies initiatives and funding, regulatory support and approvals, public health campaigns, and advancements in vaccine technology.

Pneumococcal Vaccine Market Analysis:

Major Market Drivers: The rise in the number of target diseases, along with governing agencies initiatives worldwide, is facilitating the market growth.

Key Market Trends: The growing investments in research and development (R&D) activities and increasing number of pneumonia diseases are positively influencing the market.

Geographical Trends: North America holds the largest segment because of strong healthcare infrastructure and ongoing innovations in technology.

Competitive Landscape: Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd., among many others.

Challenges and Opportunities: While the market faces challenges like medical concerns associated with the vaccine, which impacts the market, it also encounters opportunities in the development and approval of novel vaccines.

Pneumococcal Vaccine Market Growth Factors:

Rising healthcare spending

High healthcare spending allows governments and private healthcare sectors to invest more in vaccination programs, leading to enhanced access and cost-effectiveness of pneumococcal vaccines, thereby increasing vaccination coverage rates across populations. In line with this, increasing healthcare spending often translates into better healthcare infrastructure, including vaccination clinics, distribution networks, and trained healthcare professionals. This infrastructure aids in the management and advocacy for pneumococcal vaccines, thus contributing to the growth of the market. Furthermore, high healthcare spending can lead to an increasing investment in research and development (R&D) activities by pharmaceutical companies, which encourages the enhancement of pneumococcal vaccines that work better, cover more serotypes or need fewer doses. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the health spending share of GDP is forecasted to grow from 17.3 percent in 2022 to 19.7 percent in 2032.

Growing aging population

Older people are more prone to pneumococcal infections, including pneumonia or invasive pneumococcal disease, due to weakened immune systems and underlying health conditions. This increasing vulnerability is leading to high utilization of pneumococcal vaccines to avoid such severe illnesses. Besides this, many governing agencies and healthcare organizations recommend pneumococcal vaccination for elderly populations as part of routine immunization schedules, which encourages healthcare providers and older adults to prioritize vaccination, thereby driving the pneumococcal vaccine demand. In addition, healthcare sectors prioritize preventive care strategies for aging populations to improve their health and minimize hospital readmissions. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 billion worldwide.

Increasing prevalence of sepsis

As per the content updated in 2024 on the website of the World Health Organization (WHO), almost 20 million of all estimated sepsis cases worldwide occurred in children under 5 years of age. Streptococcus pneumoniae, which causes pneumococcal infections, is one of the leading causes of sepsis, especially among children those with weakened immune systems. The rising occurrence of sepsis caused by pneumococcal infections underlines the importance of preventive approaches such as vaccination. In addition, vaccination against Streptococcus pneumoniae significantly reduces the risk of pneumococcal infections, including those that can lead to sepsis. By preventing pneumococcal diseases, vaccines help mitigate the overall burden of sepsis in healthcare settings. Apart from this, they reduce the overall burden of sepsis in care settings by preventing pneumococcal diseases. Furthermore, the administration of pneumococcal vaccines as a protective strategy against sepsis is increasing their sales. Prevention of sepsis morbidity and mortality through vaccination in public health intervention across the globe is supporting the market growth.

Pneumococcal Vaccine Market Segmentation:

IMARC Group provides an analysis of the pneumococcal vaccine industry trends in each segment, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on vaccine type, product type, distribution channel, and end user.

Breakup by Vaccine Type:

Pneumococcal Conjugate Vaccine

Pneumococcal Polysaccharide Vaccine

Pneumococcal conjugate vaccine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. According to the report, pneumococcal conjugate vaccine represents the largest segment.

The pneumococcal conjugate vaccine (PCV) is one of the most important products in the market because of its effectiveness in improving public health particularly among children below five years and elderly people. PCVs are aimed at offering protection against various serotypes of the streptococcus pneumoniae bacterium, which is known to cause severe and sometimes fatal conditions such as pneumonia, meningitis, and sepsis. PCVs have been proven to be effective in reducing the incidence of these diseases, which makes it possible to be incorporated in national immunization programs.

Breakup by Product Type:

Prevnar 13

Synflorix

Pneumovax 23

Prevnar 13 holds the largest share of the industry

A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes Prevnar 13, synflorix, and pneumovax 23. According to the report, Prevnar 13 accounts for the largest market share.

Prevnar 13 is highly preferable due to its effectiveness in preventing infections caused by Streptococcus pneumoniae bacteria. This vaccine is particularly notable for its broad coverage against thirteen different strains of the bacteria. Its incorporation in national immunization programs worldwide is greatly impacting the cases of pneumococcal diseases especially in young children and older individuals. Moreover, its well-established clinical effectiveness and safety profile are ensuring its escalated utilization throughout the world, making it an essential pillar of modern healthcare systems in combating pneumococcal diseases.

Breakup by Distribution Channel:

Distribution Partner Companies

Non-Governmental Organizations (NGO)

Government Authorities

Non-governmental organizations (NGO) represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes distribution partner companies, non-governmental organizations (NGO), and government authorities. According to the report, non-governmental organizations (NGO) represent the largest segment.

Non-governmental organizations (NGO) contribute to market dynamics through various initiatives, including funding support for vaccination programs, raising awareness about the importance of pneumococcal immunization, and collaborating with governments and pharmaceutical companies to ensure affordability and availability of vaccines. NGOs also engage in R&D activities to improve vaccine efficacy and promote vaccination campaigns aimed at vulnerable populations such as children and the elderly. Their advocacy efforts also address socio-economic disparities in healthcare access, making pneumococcal vaccines more accessible and impactful worldwide.

Breakup by End User:

Pediatrics

Adults

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes pediatrics and adults.

Children, especially infants and toddlers, are highly vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and sepsis. Vaccination against pneumococcus bacteria is therefore recommended as part of routine childhood immunization schedules worldwide. The effectiveness of pneumococcal vaccines in preventing these infections is significantly reducing morbidity and mortality rates among children globally. Moreover, public health initiatives and immunization programs focused on pediatric populations are contributing to the pneumococcal vaccines market statistics.

As adults are aging, especially those over 65 or with underlying health conditions, they are becoming more vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and septicemia. Vaccination in adults helps reduce the risk of these infections and their associated complications, improving overall health outcomes and reducing healthcare costs. Additionally, adults often serve as carriers of pneumococcal bacteria, potentially spreading it to more vulnerable populations like children and the elderly people.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest pneumococcal vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pneumococcal vaccine.

As per the content updated in 2023 on the website of Centers for Medicare & Medicaid Services, U.S. health care spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. The increasing healthcare expenditure reflects a greater emphasis on improving patient outcomes and reducing overall healthcare costs through innovative technologies. Moreover, North America has stringent regulatory frameworks and strong government support for immunization programs that contribute significantly to the growth of the market. The prevalence of pneumococcal diseases in North America, coupled with increasing awareness among healthcare professionals and the general population about the benefits of vaccination, is also driving the demand for pneumococcal vaccines.

Competitive Landscape:

The market pneumococcal vaccine market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pneumococcal vaccine industry include Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd, and Walvax Biotechnology Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players are investing in research and development (R&D) activities aimed at developing next-generation vaccine formulations. They are also expanding manufacturing capabilities to meet the growing global demand. Key players are also investing in clinical trials and studies to demonstrate efficacy and safety. They are also adopting innovative technologies for vaccine production and distribution. Many companies are implementing vaccination campaigns and educational programs to increase awareness and vaccine uptake. Key players are collaborating with other industry stakeholders, government agencies, healthcare organizations, and research institutions to expand their market reach and develop new products. For instance, in 2023, Vaxcyte, Inc. collaborated with Lonza for a new commercial manufacturing agreement. With this collaboration, Vaxcyte planned to expand its commercial manufacturing capacity for its PCV candidates.

Pneumococcal Vaccine Market Recent News:

January 26, 2024: Pfizer Inc. received marketing authorization from the Committee of Medicinal Products designed for Human Use (CHMP) of the European Medicines Agency (EMA) for its 20-valent pneumococcal conjugate vaccine candidate (20vPnC).

April 22, 2024: Takeda, Astellas and Sumitomo Mitsui Banking announced an agreement to establish a joint venture company for incubation of early drug discovery programs.

Key Questions Answered in This Report

  • 1. What was the size of the global pneumococcal vaccine market in 2023?
  • 2. What is the expected growth rate of the global pneumococcal vaccine market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global pneumococcal vaccine market?
  • 4. What are the key factors driving the global pneumococcal vaccine market?
  • 5. What is the breakup of the global pneumococcal vaccine market based on the vaccine type?
  • 6. What is the breakup of the global pneumococcal vaccine market based on the product type?
  • 7. What is the breakup of the global pneumococcal vaccine market based on the distribution channel?
  • 8. What are the key regions in the global pneumococcal vaccine market?
  • 9. Who are the key players/companies in the global pneumococcal vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pneumococcal Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Pneumococcal Conjugate Vaccine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pneumococcal Polysaccharide Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Prevnar 13
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Synflorix
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Pneumovax 23
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Distribution Partner Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-Governmental Organizations (NGO)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Government Authorities
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Astellas Pharma Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 GlaxoSmithKline Plc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Merck & Co. Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Panacea Biotec Ltd.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Pfizer Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Sanofi S.A.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Serum Institute of India Pvt Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Walvax Biotechnology Co. Ltd.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials

List of Figures

  • Figure 1: Global: Pneumococcal Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Pneumococcal Vaccine Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pneumococcal Vaccine Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pneumococcal Vaccine Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Pneumococcal Vaccine Market: Breakup by Product Type (in %), 2023
  • Figure 6: Global: Pneumococcal Vaccine Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Pneumococcal Vaccine Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Pneumococcal Vaccine Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Pneumococcal Vaccine (Pneumococcal Conjugate Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pneumococcal Vaccine (Pneumococcal Polysaccharide Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pneumococcal Vaccine (Prevnar 13) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pneumococcal Vaccine (Prevnar 13) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pneumococcal Vaccine (Synflorix) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pneumococcal Vaccine (Synflorix) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pneumococcal Vaccine (Pneumovax 23) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pneumococcal Vaccine (Pneumovax 23) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pneumococcal Vaccine (Distribution Partner Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pneumococcal Vaccine (Non-Governmental Organizations-NGO) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pneumococcal Vaccine (Government Authorities) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pneumococcal Vaccine (Government Authorities) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pneumococcal Vaccine (Pediatrics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pneumococcal Vaccine (Pediatrics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pneumococcal Vaccine (Adults) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pneumococcal Vaccine (Adults) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Pneumococcal Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Pneumococcal Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Pneumococcal Vaccine Market: Breakup by Country (in %), 2023
  • Figure 78: Global: Pneumococcal Vaccine Industry: SWOT Analysis
  • Figure 79: Global: Pneumococcal Vaccine Industry: Value Chain Analysis
  • Figure 80: Global: Pneumococcal Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pneumococcal Vaccine Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pneumococcal Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Pneumococcal Vaccine Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 4: Global: Pneumococcal Vaccine Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Pneumococcal Vaccine Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Pneumococcal Vaccine Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Pneumococcal Vaccine Market: Competitive Structure
  • Table 8: Global: Pneumococcal Vaccine Market: Key Players